Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Presentations
    • Press Releases
    • Scientific publications
    • Events
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Presentations
    • Press Releases
    • Scientific publications
    • Events
  • Contact

Archives

Monthly Archive for: "Marzo, 2021"
Home » Archivi per Marzo 2021
 0

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy

BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]

READ MORE
0

Nouscom is presenting at the virtual Spring Private Company Showcase 2021 on March 11th

Find out more about the program and register here: Spring Private Company Showcase « Solebury Trout Access

READ MORE
0

Nouscom is presenting at the Biocapital Europe 2021 on March 11th

Find out more about the program and register here: https://www.biocapitaleurope.com/programme/

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!